studies

mML - 2nd line (L2), pembrolizumab alone vs. chemotherapy, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.74 [0.57; 0.96] KEYNOTE-002 (2 mg/kg), 2015 0.86 [0.67; 1.10] 0.80[0.67; 0.96]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%719moderatenot evaluable progression or deaths (PFS)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.50 [0.39; 0.64] KEYNOTE-002 (2 mg/kg), 2015 0.57 [0.45; 0.73] 0.53[0.45; 0.64]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%719moderatenot evaluable objective responses (ORR)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 8.16 [3.74; 17.80] KEYNOTE-002 (2 mg/kg), 2015 6.11 [2.77; 13.47] 7.07[4.06; 12.33]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%719moderatenot evaluable TRAE (any grade)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.76 [0.45; 1.26] KEYNOTE-002 (2 mg/kg), 2015 0.56 [0.34; 0.93] 0.65[0.46; 0.93]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.54 [0.32; 0.91] KEYNOTE-002 (2 mg/kg), 2015 0.44 [0.25; 0.76] 0.49[0.33; 0.71]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable TRAE leading to death (grade 5)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 1.92 [0.06; 57.48] KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69] 1.42[0.11; 18.63]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable TRAE leading to discontinuation (any grade)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 1.65 [0.70; 3.87] KEYNOTE-002 (2 mg/kg), 2015 0.85 [0.32; 2.25] 1.23[0.65; 2.35]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201521%699moderatenot evaluable TRAE leading to discontinuation (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 2.73 [0.85; 8.76] KEYNOTE-002 (2 mg/kg), 2015 1.46 [0.40; 5.25] 2.06[0.87; 4.87]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Alopecia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69] 0.96[0.06; 15.38]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Anaemia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.05 [0.00; 0.88] KEYNOTE-002 (2 mg/kg), 2015 0.10 [0.01; 0.81] 0.08[0.01; 0.43]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Arthralgia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.06; 15.39] KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.06; 15.48] 0.96[0.13; 6.84]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Asthenia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.06; 15.39] KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.06; 15.48] 0.96[0.13; 6.84]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Colitis TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 2.90 [0.30; 28.13] KEYNOTE-002 (2 mg/kg), 2015 0.48 [0.02; 14.37] 1.66[0.25; 11.00]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Constipation TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69] 0.96[0.06; 15.38]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69] 0.96[0.06; 15.38]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 1.28 [0.28; 5.81] KEYNOTE-002 (2 mg/kg), 2015 0.16 [0.01; 3.17] 0.68[0.10; 4.48]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 2015233%699moderatenot evaluable Dry skin TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69] 0.96[0.06; 15.38]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Fatigue TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.23 [0.05; 1.10] KEYNOTE-002 (2 mg/kg), 2015 0.23 [0.05; 1.11] 0.23[0.08; 0.70]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Hepatitis TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 3.85 [0.17; 86.06] KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69] 2.26[0.20; 25.79]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69] 0.96[0.06; 15.38]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Hypophysitis TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] KEYNOTE-002 (2 mg/kg), 2015 1.93 [0.06; 57.80] 1.43[0.11; 18.64]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69] 0.96[0.06; 15.38]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Leucopenia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.07 [0.00; 1.17] KEYNOTE-002 (2 mg/kg), 2015 0.07 [0.00; 1.17] 0.07[0.01; 0.50]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Maculopapular rash TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 1.92 [0.06; 57.48] KEYNOTE-002 (2 mg/kg), 2015 1.93 [0.06; 57.80] 1.92[0.17; 21.29]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Myalgia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.48 [0.02; 14.29] KEYNOTE-002 (2 mg/kg), 2015 1.93 [0.17; 21.50] 1.21[0.17; 8.64]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Nausea TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.23 [0.03; 2.12] KEYNOTE-002 (2 mg/kg), 2015 0.12 [0.01; 2.24] 0.18[0.03; 1.07]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Neutropenia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.08 [0.00; 1.39] KEYNOTE-002 (2 mg/kg), 2015 0.08 [0.00; 1.40] 0.08[0.01; 0.60]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Pancreatitis TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 1.92 [0.06; 57.48] KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69] 1.42[0.11; 18.63]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Paraesthesia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69] 0.96[0.06; 15.38]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Peripheral neuropathy TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.24 [0.01; 5.29] KEYNOTE-002 (2 mg/kg), 2015 0.24 [0.01; 5.32] 0.24[0.03; 2.13]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 5.81 [0.29; 116.90] KEYNOTE-002 (2 mg/kg), 2015 1.93 [0.06; 57.80] 3.58[0.38; 34.02]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Pruritus TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69] 0.96[0.06; 15.38]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Rash TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69] 0.96[0.06; 15.38]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Thrombocytopenia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.23 [0.03; 2.12] KEYNOTE-002 (2 mg/kg), 2015 0.12 [0.01; 2.24] 0.18[0.03; 1.07]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Uveitis TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 1.92 [0.06; 57.48] KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69] 1.42[0.11; 18.63]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Vitiligo TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] KEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69] 0.96[0.06; 15.38]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable Vomiting TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.23 [0.03; 2.12] KEYNOTE-002 (2 mg/kg), 2015 0.24 [0.03; 2.13] 0.24[0.05; 1.12]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-002 (2 mg/kg), 201520%699moderatenot evaluable0.010.01.0relative treatment effectwww.metaEvidence.org2024-07-01 16:21 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 286,69,129 - treatments: 359,575,577,576,869

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons